 Shares of Arcus Biosciences Inc. RCUS, -1.23 were down 17.2 in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that its developing with Gilead Sciences Inc. GILD, -0.39 improved progression-free survival and overall response rate ORR in a Phase 2 clinical study. The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing to some and it remains to be seen how much GILDRCUSs combo can truly differentiate vs. 